A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.

Trial Profile

A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BOSTON II
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Nov 2015 Planned primary completion date changed from 1 Feb 2018 to 1 Sep 2019 as reported by ClinicalTrials.gov record.
    • 04 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top